Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Champions Oncology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2026 was -9.33%.
The historical rank and industry rank for Champions Oncology's ROC (Joel Greenblatt) % or its related term are showing as below:
CSBR'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1928.22 Med: -31.88 Max: 45.23
Current: -24.76
During the past 13 years, Champions Oncology's highest ROC (Joel Greenblatt) % was 45.23%. The lowest was -1928.22%. And the median was -31.88%.
CSBR's ROC (Joel Greenblatt) % is ranked better than 71.47% of 1318
companies
in the Biotechnology industry
Industry Median: -294.23
vs CSBR: -24.76
Champions Oncology's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
Champions Oncology (NAS:CSBR) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Champions Oncology ROC (Joel Greenblatt) % Related Terms
Champions Oncology ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Champions Oncology's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSBR vs SEER, RLYB, FBIO: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Champions Oncology's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Champions Oncology's ROC (Joel Greenblatt) % falls into.
Champions Oncology ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jan. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -9.33% mean?
Champions Oncology (CSBR) has a ROC (Joel Greenblatt) % of -9.33% as of Jan. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Champions Oncology and its competitors. According to the industry distribution chart, Champions Oncology ranks #376 out of 1318 companies in the Biotechnology industry, placing it in the top 28.5%.
Is Champions Oncology's ROC (Joel Greenblatt) % too high?
Champions Oncology's current ROC (Joel Greenblatt) % is -9.33%. Based on the distribution chart, Champions Oncology ranks #376 out of 1318 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Champions Oncology has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's ROC (Joel Greenblatt) % compare to SEER and RLYB?
According to the Biotechnology industry distribution chart, Champions Oncology ranks #376 out of 1318 companies for ROC (Joel Greenblatt) %. This puts Champions Oncology in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Champions Oncology and its competitors. Champions Oncology's current ROC (Joel Greenblatt) % is -9.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Fairly Valued. The stock's GF Value™ is $6.65, compared to a current price of $6.07 — trading 8.8% below its estimated fair value. The current ROC (Joel Greenblatt) % is -9.33%. Champions Oncology's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Champions Oncology (CSBR), the current ROC (Joel Greenblatt) % is -9.33% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Champions Oncology (CSBR) Overvalued in 2026?
Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued.
The current stock price of $6.07 is trading 8.8% below its estimated GF Value™ of $6.65.
GuruFocus considers Champions Oncology to be Fairly Valued.
Key valuation signals for CSBR:
ROC (Joel Greenblatt) %: -9.33%
GF Value™: $6.65 vs. price of $6.07 (8.8% below fair value)
No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
61GF Score
Get the complete analysis for CSBR
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBR has been successfully added to your 
